(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay? - 2Home Mechanization Frameworks for Brilliant Residing
- 3Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- 4From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- 5Ancient eggshells shed new light on crocodiles that hunted prey from trees
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Courageous Climbing: Trails and Stuff for Outside Lovers
- Investigating the Medical advantages of Aloe Vera
- 6 U.S. States for Climbing
- A Manual for Nations to Head out To
- Family-Accommodating Snow Sports Experiences
- 5 Wellbeing Applications Assist You With remaining Fit
- US FDA unveils new pathway to approve personalized therapies
